Cartalax

Review AED and T-31 research in renal cultures, chondrocytes and human stem cells, separating cartilage markers from proven joint repair.

Ara-290

Review ARA-290 and cibinetide human neuropathy studies, corneal nerve measurements, pain outcomes and safety findings with evidence limits.

Cerebrolysin

Compare CARS, CASTA and CERE-LYSE findings, distinguishing early recovery signals, primary endpoints, rehabilitation context and preparation identity.

Chonluten

Examine Chonluten immune-cell signaling and inflammatory findings, including context-dependent responses and the limits of respiratory treatment claims.

MOTS-C

Explore MOTS-c metabolic research, mouse performance findings, human exercise observations and FDA evidence gaps without overstating clinical benefits.

SLU-PP-332

Read the SLU-PP-332 evidence on ERR signaling, mouse exercise capacity, metabolism and aging kidneys, with clear boundaries for human claims.

Thymosin Alpha-1

Review thymosin alpha-1 sepsis trials, hepatitis B studies, vaccine-response research and safety concerns with clear evidence limits.

PEG MGF

Assess PEG-MGF identity and half-life claims, related MGF findings, FDA safety concerns and the missing direct evidence for human recovery benefits.

Pancragen

Examine Pancragen glucose-tolerance studies in aged rhesus monkeys, including a small glimepiride comparison and limits on human treatment claims.

Crystagen

Understand Crystagen B-cell findings, the reported absence of spleen cell renewal, and the evidence needed for meaningful immune-protection claims.